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Abstract
Background: Cystic fibrosis (CF) is an autosomal recessive disorder whose incidence has long been estimated as
1/2500 live births in Caucasians. Expanding implementation of newborn screening (NBS) programs now allows a
better monitoring of the disease incidence, what is essential to make reliable predictions for disease management.
This study assessed time trends in the birth incidence of CF over a long period (35 years: 1975-2009) in an area
where CF is frequent (Brittany, France) and where NBS has been implemented for more than 20 years.
Methods: This study enrolled CF patients born in Brittany between January 1st 1975 and December 31st 2009 (n =
483). Time trends in incidence were examined using Poisson regression and mainly expressed using the average
percent change (APC).
Results: The average number of patients born each year declined from 18.6 in the late 1970’s (period 1975-79) to
11.6 nowadays (period 2005-09). The corresponding incidence rates dropped from 1/1983 to 1/3268, which
represented a decline close to 40% between these two periods (APC = -39.3%, 95% CI = -55.8% to -16.7%, p =
0.0020). A clear breakpoint in incidence rate was observed at the end of the 1980’s (p < 0.0001). However, the
incidence rate has remained quite stable since that time (annual APC = -1.0%, 95% CI = -3.0% to 1.1%, p = 0.3516).
Conclusions: This study provides an accurate picture of the evolution of the incidence of a genetic disease over a
long period and highlights how it is influenced by the health policies implemented. We observed a 40% drop in
incidence in our area which seems consecutive to the availability of prenatal diagnosis.
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Background
Cystic fibrosis (CF; OMIM#219700) is an autosomal
recessive disorder due to mutations in the CFTR (Cystic
Fibrosis Transmembrane conductance Regulator) gene,
which was cloned in 1989 [1]. Newborn screening (NBS)
for CF, which has progressively been implemented world-
wide over the past years, now allows better monitoring of
the birth incidence of CF, which appears lower than in
the past. Long estimated as 4.0/10,000 (i.e. 1/2500) live
births in Caucasians [2], the average birth incidence rate
is now 2.9/10,000 (i.e. 1/3500) in Europe [3,4].
Time trends in the birth incidence of CF have been
investigated in several studies, but the magnitude of the
reported changes varies according to the areas and to the
length of the period under study [5-8]. The trends
observed result from a complex mixture of phenomena
and have been ascribed to various health policies (as pre-
natal diagnosis, family testing [9], population-based car-
rier screening [10-12]) and/or to demographic factors (as
reduction of family size, increase of population mixing
with consecutive decline of endogamy and inbreeding
[8]).
Time trends in the birth incidence therefore depend
on the health policies implemented in the studied popu-
lation, but also on the characteristics of the population
(i.e. carrier rate, cultural attitudes toward prenatal
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diagnosis and pregnancy termination, birth rate, etc).
Monitoring of CF incidence is therefore essential to be
able to make reliable predictions for disease manage-
ment in the future.
In this study, we examined time trends in the inci-
dence of CF over a long period (the longest ever studied
to date: 35 years, 1975-2009) in an area where CF is fre-
quent (Brittany, western France), where NBS has been
implemented for a long time (since 1989) but where
carrier screening (both preconceptional screening and
prenatal screening) is not underway.
Methods
Study population
This study enrolled CF patients born in Brittany (wes-
tern France) between January 1st 1975 and December
31st 2009. Confined at the western end of Europe, Brit-
tany is a region of three million inhabitants where the
incidence of CF is among the highest in the world [13]
and where an NBS program has been under way since
1989 [14]. This particular situation led us to set up a
registry of molecular epidemiology of CF in this area, in
order to analyze temporal trends in incidence and survi-
val [13].
Brittany has a relatively homogeneous population, which
mainly results from historical waves of migrations of Celtic
people. The geographical structure of this area (peninsula)
coupled with the use, for many centuries, of a Celtic lan-
guage (the Breton) have contributed to the isolation of its
population. This resulted in low populations’ mixings and
high levels of endogamy and inbreeding.
Data sources
The patients included in the present study were extracted
from this registry, which also gathers newborn screening
and prenatal diagnosis data. As previously described [13],
patients born before the set up of NBS were retrieved
through active enquiries and a combination of data
sources (with capture-recapture studies). Patients born
since the implementation of NBS were easily collected by
consulting data from the French organization in charge of
this program (A.F.D.P.H.E.) as well as data from the genet-
ics laboratories of our area.
In order to ensure data homogeneity, the same inclu-
sion criteria were used throughout. Patients with an
equivocal diagnosis that could have been detected
through NBS were excluded from the analysis (i.e. new-
borns screened with ambiguous sweat test results and/
or CFTR mutations not clearly associated with CF, as
for example those carrying the R117H: n = 19) [15-17].
All patients born during the study period were enrolled,
including siblings as well as false-negative cases missed
by our NBS program.
Statistical analysis
Statistical analysis was performed using SAS software
(version 9.2-SAS Institute, Cary, NC, USA). The signifi-
cance level was set at p ≤ 5% for all analyses.
Birth incidence rate calculation
The birth incidence rate of CF (with its 95% confi-
dence interval-95% CI) was determined for the
whole study period, by 5-year periods and by year.
The incidence rate of a given year was calculated by
dividing the number of CF children born over that
year by:
1) Prior to the implementation of NBS: the number of
live births that occurred in Brittany over that year (data
provided by the French Institute of Statistics and Eco-
nomic Studies).
2) After the implementation of NBS: the number of
screening tests performed in Brittany over that year
(data provided by the organization in charge of the NBS
program). It is important to note that the refusal rate
for this test is extremely low in our area (< 0.01%).
Time trends analysis
Time trends in the incidence rates were examined using
Poisson regression, which enables to model count or
rate data. This approach, which derives from generalized
linear models [18], is classically used to analyze time
trends in incidence of cancers or of chronic diseases.
The analyses were conducted by considering the
whole study period, but also 5-year periods as well as
other periods of interest (defined by the time of imple-
mentation of prenatal diagnosis or newborn screening).
For all analyses, the oldest period was taken as
reference.
The changes observed in the incidence rates were
expressed by two parameters:
1) the odds-ratio (OR) with its 95% CI. The OR corre-
sponds to the exponential of the b coefficient that esti-
mates the effect of time. It indicates how much the
incidence rate observed over a period has decreased in
comparison with the reference period.
2) the average percent change (APC) with its 95% CI.
This parameter is derived from the formula ([exp(b)-1]
*100) and represents the percentage of variation
observed in the incidence rates between the periods of
interest ([Incidence Period-Incidence Reference period]/Inci-
dence Reference period). When time is coded as the year of
birth, the APC represents the annual average percent
change in the incidence rate.
All the models were fitted using the “Proc genmod”
procedure in the SAS software. A constant rate of
change was assumed over the period concerned (log-lin-
earity assumption) and the presence of under/over dis-
persion was checked by introducing the term “scale =
pearson” in the models.
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Adjusted incidence rate calculation
Prenatal diagnosis of CF was developed in the early
1980’s [19,20]. Beyond the parents of CF child(ren), pre-
natal diagnosis is offered to the 1-in-4 risk couples iden-
tified through family testing, but also, since the early
1990’s, to the 1-in-4 risk couples identified following the
in utero detection of a sonographic sign suggestive of
CF (echogenic bowel). If the fetus is found to be CF-
affected, genetic counseling is offered to the couple and
the possibility of therapeutic termination is made
available.
As we have knowledge of the number of pregnancy
terminations performed yearly after a positive prenatal
diagnosis (made by molecular biology) in our area, we
were also able to calculate an adjusted incidence rate
(by adding these data to the calculations) and therefore
to assess the impact of prenatal diagnosis on the inci-
dence rate. We also examined in detail the contexts in
which the 1-in-4 risk was discovered (i.e. the contexts in
which the PD was done), and assessed the impact of
each of these contexts on the incidence rate.
This research protocol was approved by the Comité
Consultatif sur le Traitement de l’Information en
Matière de Recherche dans le domaine de la Santé and
by the Commission Nationale d’Informatique et des
Libertés.
Results
Birth incidence rate and its time trends
A total of 483 CF children born in Brittany between
January 1st 1975 and December 31st 2009 were recorded.
Half of them (n = 243, 50.3%) were born since the
implementation of the NBS program in 1989. The CFTR
genotype could be fully determined in 96.5% of the
patients (n = 466) and 56.0% of them (n = 261) were
homozygous for the main F508del (p.Phe508del) muta-
tion. These data led to a global CF birth incidence rate
of 3.8/10,000 (95% CI = 3.4/10,000 to 4.2/10,000) in
Brittany over the study period (i.e. 1/2637).
Figure 1 shows the evolution of the annual birth inci-
dence rate of CF over the 35-year period. Despite year-
to-year variations, Poisson regression analysis revealed a
significant decrease in the incidence rate over the whole
study period (p < 0.0001). The annual APC was -1.8%
(95% CI = -2.6% to -1.0%), meaning that the incidence
rate decreased on average by 1.8% each year.
The analysis performed by 5-year periods (Tables 1
and 2) indicated that the incidence rate dropped from
5.0/10,000 (i.e. 1/1983) in the late 1970’s to 3.1/10,000
(i.e. 1/3268). The average number of CF children born
each year over these two periods decreased from 18.6 to
11.6.
Detailed examination of the data revealed a clear
breakpoint in the incidence rate at the end of the
1980’s. As illustrated in Table 2, the incidence rates of
the last four 5-year periods appeared quite similar, and
were significantly lower than those of the first three per-
iods. These rates were respectively 1.53, 1.57, 1.62 and
1.65 times lower than that of the oldest period (1975-
79). This can also be observed in Figure 2, which shows
the evolution of the birth incidence rate by 5-year
period.
The most significant change was observed when the
year 1990 was considered as the cut-off time. The inci-
dence rate decreased from 4.6/10,000 (i.e. 1/2171) before
this year to 3.2/10,000 (i.e. 1/3158) afterwards (corre-
sponding to a decline of 31.3%, p < 0.0001). One can
also note that the proportion of sibships with several CF
children significantly dropped at the same time (from
9.3% over the period 1975-1989 to 3.2% over the period
1990-2009, p = 0.0094).
The incidence rate has remained quite constant since
the early 1990’s, since when no significant decline has
been observed (annual APC = -1.0%, 95% CI = -3.0% to
1.1%, p = 0.3516).
Adjusted incidence rate
Finally, we calculated an adjusted incidence rate by tak-
ing into account the pregnancy terminations performed
after a positive prenatal diagnosis of CF in our area
(Table 3).
Since prenatal diagnosis of CF was done by molecular
techniques (i.e. 1986), 105 terminations were performed
in such a context among couples living in Brittany, i.e. a
mean of four per year. If all these affected pregnancies
had resulted in the birth of a CF child, the overall CF
incidence rate over the period 1986-2009 would have
been 4.6/10,000 (i.e. 1/2169) instead of 3.4/10,000 (i.e.
1/2946), i.e. 35.8% higher.
As shown in Table 4, most of the 105 terminations
(60.0%) were done in the parents of previous CF child
(ren), 23.8% were done in couples whose 1-in-4 risk was
identified following the ultrasound detection of a sign
suggestive of CF during pregnancy, and 16.2% were
done in 1-in-4 risk couples identified through family
testing. Table 4 also shows that, in our area, the impact
of the sonographic detection of a sign evocative of CF
during pregnancy appeared higher than the impact of
family testing.
Discussion
This study deciphers how the incidence of CF has
evolved over a long time (the longest ever studied to
date: 35 years) in an area where CF is frequent (Brittany,
France) and where population-based carrier screening-
known to significantly decrease the incidence [12]-is not
underway. It also highlights how the incidence is influ-
enced by the health policies implemented.
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This study reveals a clear fall in the incidence rate,
which dropped by 40% between the period 1975-79 and
2005-09. The observed breakpoint coincides with the
more common use of prenatal diagnosis since the end
of the 1980’s. This test has been increasingly used nota-
bly by couples identified to be at risk following NBS,
which was implemented in our area in 1989. This study
also highlights the importance of ultrasound monitoring
performed during pregnancy, which may identify new 1-
in-4 risk couples following detection of echogenic bowel.
We have been able to measure accurately the impact
of prenatal diagnosis in our area as we have an exhaus-
tive collection of its data. By including pregnancy termi-
nations in the calculations, we have shown that the
incidence rate would have been 35.8% higher than that
observed to date. The impact of this test appears parti-
cularly high in Brittany. Indeed, despite the progress
accomplished over the past decades in the field of CF,
most 1-in-4 risk couples in our area request prenatal
diagnosis and 95% choose not to continue the preg-
nancy if the fetus is affected [21].
However, the impact of prenatal diagnosis on inci-
dence rate remains relatively limited in areas where
population-based carrier screening is not implemented.
Indeed, this test can only be offered to 1-in-4 risk cou-
ples related to a CF patient or to a carrier child identi-
fied through NBS. Therefore, most carrier couples are at
risk without knowing it, and can give birth to a CF
child. In our area, one individual in 29 is a healthy car-
rier. Only the implementation of carrier screening may
significantly reduce the incidence, as recently shown in
an Italian area [12]. Population-based carrier screening
consists in offering genetic testing to all the couples
planning a pregnancy in a given population. Aware of
their high risk, the couples found to have a 1-in-4 risk
may opt for prenatal diagnosis and may choose to ter-
minate the pregnancy if the fetus is CF-affected. Such a
program is not underway in our area, and this is prob-
ably why the incidence has remained stable since the
early 1990’s.
The present study provides an accurate picture of the
evolution of the incidence of CF on the scale of an
entire population over a long period. It relies on exhaus-
tive collection of data in a large region whose geographi-
cal situation (peninsula) means that the data are well
centralized and easier to collect. A few biases may have
affected our study. Since 1989, an NBS program has
been implemented in our area, which ensures quasi-
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Figure 1 Evolution of the annual birth incidence rate of cystic fibrosis in Brittany over the period 1975-2009. As statistical analysis
revealed that the most significant change in incidence rate was observed when the year 1990 was considered as the cut-off time, we plotted
the trendlines independently for the periods 1975-1989 and 1990-2009.
Table 1 Birth incidence rates of cystic fibrosis in Brittany by 5-year period (period 1975-2009).
Period No. patients No. births Incidence (95% CI) (1/xxxx) Incidence (95% CI) (/10,000)
1975-1979 93 184407 1/1983 (1/2413; 1/1629) 5.0 (4.1; 6.1)
1980-1984 80 189746 1/2372 (1/3880; 1/1450) 4.2 (2.6; 6.9)
1985-1989 82 179446 1/2188 (1/3573; 1/1340) 4.6 (2.8; 7.4)
1990-1994 56 169926 1/3034 (1/5123; 1/1797) 3.3 (2.0; 5.5)
1995-1999 56 174412 1/3115 (1/5258; 1/1845) 3.2 (1.9; 5.4)
2000-2004 58 186054 1/3208 (1/5396; 1/1907) 3.1 (1.9; 5.2)
2005-2009 58 189563 1/3268 (1/5498; 1/1943) 3.1 (1.8; 5.1)
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exhaustive registration of new cases at birth. False-nega-
tive cases are always a possibility, but the cases reported
so far (which are few in number in the last decade) have
been included in the calculations (n = 10). Newborn
screening may also diagnose atypical cases that do not
meet all the criteria for CF [22,23]. To overcome this
problem, which may alter time trends, equivocal diag-
noses were excluded from the analysis [15]. Another pit-
fall that could affect our findings is under-reporting
and/or under-diagnosis of cases predating the setting of
NBS. The active combination of data sources and the
use of capture-recapture studies may have limited this
phenomenon. Anyway, in such a situation, the incidence
rate would have been still greater in that period, and the
observed drop still higher.
Several studies have analyzed time trends in the inci-
dence of CF. While most have reported a decline, some
have not observed any temporal change [24]. The find-
ings are however difficult to compare because the stu-
dies have been conducted over various periods and in
areas that have not implemented similar public health
policies and that have different attitudes towards prena-
tal diagnosis.
The oldest studies were conducted from registry data
(prone to under-diagnosis and/or under-reporting),
mainly in countries that did not practice NBS. In
Canada, time trends were analyzed over the period
1971-2000 and a linear decline was noted since 1988,
which coincided with the increased use of family testing
and prenatal diagnosis services [6]. In the Netherlands,
the incidence rate observed over the period 1974-1997
(2.1/10,000 i.e. 1/4780) was found to be significantly
lower than that estimated over a previous period (1961-
1965: 2.9/10,000 i.e. 1/3600) [7,25]. In the UK, a con-
stant decline in incidence rate was also observed over a
26-year period (1968-1994) from data of the UK Regis-
try [5].
More recent studies have analyzed time trends in the
incidence rate since the implementation of NBS [8]. The
region of East Anglia (UK), where NBS has been in
place since 1981, experienced a constant decline over
the period 1981-1990. In the State of Victoria (Austra-
lia), a 17% reduction in the birth incidence of CF was
seen following the introduction of NBS in 1989 [26].
The incidence dropped from 3.96/10,000 (i.e. 1/2525)
live births over the period 1979-1988 to 3.28/10,000 (i.e.
1/3050) over the period 1989-2006. This was attributed
to the uptake of prenatal diagnosis, especially in families
identified by NBS. Brittany appears to be similar in var-
ious respects, such as the date of implementation of an
Table 2 Results of the time trend analysis: odds-ratio (OR) and average percent change (APC) associated with each 5-
year period (period 1975-2009).
Period Incidence (1/xxxx) Incidence (/10,000) OR (95% CI) eb APC (95% CI) (eb-1)*100 p
1975-1979 1/1983 5.0 ref. ref. -
1980-1984 1/2372 4.2 0.84 (0.63; 1.12) -16.4% (-37.4%; 11.6%) 0.2243
1985-1989 1/2188 4.6 0.91 (0.68; 1.21) -9.4% (-32.0%; 20.7%) 0.5007
1990-1994 1/3034 3.3 0.65 (0.47; 0.90) -34.7% (-52.6%; -10.0%) 0.0093
1995-1999 1/3115 3.2 0.64 (0.46; 0.88) -36.3% (-53.8%; -12.3%) 0.0058
2000-2004 1/3208 3.1 0.62 (0.45; 0.85) -38.2% (-55.0%; -15.1%) 0.0029
2005-2009 1/3268 3.1 0.61 (0.44; 0.83) -39.3% (-55.8%; -16.7%) 0.0020
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Figure 2 Evolution of the birth incidence rate of cystic fibrosis in Brittany by 5-year period, over the period 1975-2009.
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NBS program, the attitudes towards request of preg-
nancy terminations, etc. Nevertheless, the decline we
observed in our area is rather higher and may, in part,
result from the greater uptake of family testing and the
efficiency of routine ultrasound monitoring of preg-
nancy, which is, in our country, supported by our health
care system.
In the US, a significant decline has been observed in
the States of Wisconsin and of Massachusetts since the
implementation of NBS (in 1994 and 1999, respectively)
[11,27], whereas no temporal trend has been noted in
the State of Colorado, which has been screening new-
borns for longer (since 1982) [24]. In Massachusetts
there has also been reported a change in the composi-
tion of the screened cohort (notably a decrease in the
proportion of the main F508del/F508del genotype)
which coincides with the implementation of carrier
screening [11]. As in Colorado, we did not find such a
change in our population over time.
A greater decline has recently been found in an area
of northern Italy (Veneto/Trentino Alto Adige) over the
period 1993-2007, particularly in the region where car-
rier screening is underway (mean annual decrease of
0.24/10,000) [12]. The authors have also noted a signifi-
cant correlation between the increase in the number of
1-in-4 risk couples identified and the decline in
incidence.
Conclusion
This study highlights that the time trends observed in
the incidence rate depend on the health policies imple-
mented in the studied population (i.e. newborn screen-
ing, prenatal diagnosis, carrier screening, etc), but also
on the characteristics of the population (i.e. carrier rate,
cultural attitudes toward prenatal diagnosis and preg-
nancy termination, birth rate, etc).
We show, in this study, that the birth incidence of
CF has dropped in our area following the implementa-
tion of prenatal diagnosis. However, the birth incidence
appears now quite stable. The sole strategy that could
strongly modify the current incidence of CF would be
the routine carrier screening of couples planning a
pregnancy. Implementation of such a program has pro-
ven successful in reducing the incidence of CF in the
State of Massachusetts [11] or in Northern Italy [12],
but also the incidence of other diseases, such as thalas-
semia [28].
Improvement in survival of CF patients as well as in
assisted reproduction techniques should help alter the
disease dynamics in the future. It is therefore essential
to keep on monitoring the incidence to be able to make
reliable disease predictions. It is also crucial to maintain
and strengthen efforts to improve clinical management
and patients’ quality of life.
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